Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

Kanji Takahashi,1 Masahito Ohji,2 Hiroko Terasaki,3 Shigeru Honda,4 Philippe Margaron,5 Tadhg Guerin,6 Mitsuko Yuzawa,7 On behalf of the EVEREST II Japanese investigators 1Department of Ophthalmology, Kansai Medical University, Osaka, Japan; 2Department of Ophthalmology, Shiga University...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T, Yuzawa M
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Japanese
polypoidal choroidal vasculopathy
ranibizumab
neovascular age-related macular degeneration
verteporfin photodynamic therapy
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/b912681db6ad4498925c230ba5d2dcaf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares